Covid-19: Maharashtra govt to issue circular for rational use of remdesivir

Apart from this, FDA minister Dr Rajendra Shingne said a special campaign will be launched against the black marketing of the anti-viral injection in the state

remdesivir, coronavirus
Tope visited government hospitals in Bhandara, Gondia and Nagpur to take stock of the situation and steps taken by the administration.
Press Trust of India Nagpur
2 min read Last Updated : Sep 25 2020 | 6:00 PM IST

Maharashtra Health Minister

Rajesh Tope on Friday said the state government will issue circular within 24 hours to all doctors and COVID-19 hospitals for rational use of remdesivir injections in the treatment of coronavirus infection.

Apart from this, FDA minister Dr Rajendra Shingne said a special campaign will be launched against the black marketing of the anti-viral injection in the state.

The ministers were addressing the media after a review meeting on the COVID-19 situation in East Vidarbha.

Tope visited government hospitals in Bhandara, Gondia and Nagpur to take stock of the situation and steps taken by the administration.

When asked about excess use and shortage of remdesivir in COVID-19 hospitals, Tope said, "Rational use of the injection is important and it should not be administered as soon as a patient is admitted."

Doctors and COVID-19 hospitals will be given directions on how to use remdesivir and a circular will be issued within 24 hours, he said.

Meanwhile, speaking about the supply of the drug, Shingne said, "By September 30, around 1.10 lakh remdesivir injections will be available in Maharashtra from five to six pharmaceutical companies that are producing the drug."

The FDA along with the home department will launch a special campaign against black marketing of remdesivir across the state and the initiative has already started in Mumbai, the minister said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMaharashtra governmentMaharashtraCoronavirus Tests

First Published: Sep 25 2020 | 5:28 PM IST

Next Story